Boxer Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-375,000
Closed -$19.8M – 66
2026
Q1
$19.8M Hold
375,000
– – 2.6% 8
2025
Q4
$15.2M Buy
+375,000
New +$8.67M 3.32% 8
2025
Q1
– Sell
-752,000
Closed -$4.17M – 56
2024
Q4
$4.17M Buy
+752,000
New +$5.09M 0.35% 42

Other funds holding TERN

Boxer Capital Management's TERN Position: Q2 2026 in Review

Boxer Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 375,000 shares — an estimated $19.8M sold.

Boxer Capital Management first reported a position in TERN in Q4 2024 and held it in 3 quarters. The position peaked at $19.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • Boxer Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Boxer Capital Management sold 375,000 Terns Pharmaceuticals shares in Q2 2026, an estimated $19.8M.
  • Boxer Capital Management first reported a position in Terns Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Boxer Capital Management's Terns Pharmaceuticals position peaked at $19.8M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.